Global Biosimilars Market

Vaccines Market Definition

The vaccines market consists of sales of vaccines and related services by entities (organizations, sole traders and partnerships) that produce vaccines to prevent various diseases. Vaccines are biological preparations that stimulate the immune system and prepare it to fight future infections caused by pathogens. They trigger the production of antibodies against pathogens or any foreign matter that enters the body. Vaccines can be administered orally, through injections or by aerosol. Vaccine doses are administered to both children (pediatric vaccines) and adults based on the schedule set for each vaccine. For adults, the vaccines are recommended based on age, health condition, prior vaccinations and occupation. The vaccines market is segmented into anti-infective vaccines; anti-cancer vaccines; and other-vaccines. Only goods and services traded between entities or sold to end consumers are included. Vaccines are preventative medicines which are administered to the general population or to those vulnerable in a population as a precautionary measure to combat a disease, they may include single or multiple doses. Vaccines work by mimicking the infectious bacteria or virus that cause a disease. They energize the body’s immune system to build up a defensive mechanism against the infectious virus or bacteria without causing the disease. Vaccines contain weakened versions of bacteria or virus, and some contain only part of the bacteria or virus. Specific vaccines also contain only the genetic material for a specific protein which directs the body to produce similar type of protein.

Central Nervous System Drugs Market Definition

The central nervous system (CNS) drugs market consists of sales of central nervous system drugs and related services by entities (organizations, sole traders and partnerships) that manufacture central nervous system drugs that are used in the treatment of diseases affecting the brain or spinal cord. The CNS drugs include anesthetics, anticonvulsants, antiemetics, antiparkinsonian agents, CNS stimulants, analgesics, and sedatives. Neurological diseases such as Epilepsy, Parkinson and psychological indications such as depression, and dementia are generally treated through these CNS drugs. Nervous system disorders are defined as disorders that affect the brain as well as the nerves found throughout the human body and the spinal cord. Structural, biochemical or electrical abnormalities in the brain, spinal cord or other nerves can result in a range of symptoms. Some of the common clinical indications of such disorders include paralysis, muscle weakness, poor coordination, loss of sensation, seizures, confusion, pain and altered levels of consciousness. These also include mental health conditions such as depression and post-traumatic stress disorder (PTSD). The market for CNS disorder drugs comprises of drugs that work in different ways depending on the type of disease by suppressing or boosting the brain activities.

CAR-T Therapy Market Definition

The chimeric antigen receptor -T therapy market consists of sales of CAR-T therapy products and related services by entities (organizations, sole traders and partnerships) that develop chimeric antigen receptor (CAR) T-cell therapies to treat blood cancers. CAR-T therapy is type of immunotherapy in which T-cells taken from patient’s blood are modified in a laboratory with the addition of a special protein receptor that grants T-cells the power to recognize as well as kill cancer cells easily, along with infusing the same back into that patient. This special protein receptor, known as the chimeric antigen receptor (CAR), attaches to a specific protein on a patient’s cancer cells. The infused cells multiply and prevail in the patient’s body as living drugs. This industry includes establishments that are involved in the research and development to introduce new targeted cell therapies for treating indications related mostly to hematological malignancies. However, some of the pipeline CAR-T therapies are aimed at targeting solid tumors including pancreatic cancer, breast cancer, ovarian cancer, gastric cancer, kidney cancer, brain tumor, and other cancer types.

The enzyme market consists of sales of enzymes to treat diseases. An enzyme is a protein or RNA formed by living cells that are extremely specific to its substrates and highly catalytic. Enzymes constitute a very significant class of biological macromolecular catalysts. Enzymes that are used in medical applications in their isolated or conjugated form with other drugs or therapies are known as therapeutic enzymes. Therapeutic enzymes are used in the treatment of various diseases including cancer, inflammatory disorders, cardiovascular diseases, and pain management. The main product types of enzymes are asparginase, lipase, protease, nattokinase, chitinase, serratiopeptidase, collagenase, ligase, and others. A protease is an enzyme that catalyzes proteolysis, which breaks proteins down into smaller polypeptides or single amino acids and promotes the formation of new protein products. The enzymes are used for the treatment of leukemia, stomach disorders, antitumor, skin ulcers, gauche disease, Fabry disease, and others and are used by drug manufacturers, hospitals, private clinics, and research laboratories. The enzymes market research report is one of a series of new reports from The Business Research Company that provides enzymes market statistics, including enzymes industry global market size, regional shares, competitors with an enzymes market share, detailed enzymes market segments, market trends, and opportunities, and any further data you may need to thrive in the enzymes industry. This enzymes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global enzymes market is expected to grow from $9.40 billion in 2021 to $10.25 billion in 2022 at a compound annual growth rate (CAGR) of 9.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, affecting many markets across the globe. The enzymes market is expected to reach $17.45 billion in 2026 at a CAGR of 14.2%. The growing prevalence of cancer requiring drug-metabolizing enzymes (DMEs) for chemotherapy is expected to drive the growth of the enzyme market in the coming years. The activation of enzymes in the human body help destroy the cancer cells and breaks down the tumor. The expression and function of drug-metabolizing enzymes (DMEs) in cancer patients' tumor tissues and metabolic organs is therefore essential and help patients for whom reaction to anticancer drugs and response to chemotherapy is low. According to the World Health Organization (WHO), 10 million deaths occurred in 2020 due to cancer and about 70% of deaths from cancer occur in low- and middle-income countries. Therefore, the increasing prevalence of cancer that can be cured using therapeutic enzymes is predicted to drive the growth of the enzyme market. The COVID-19 outbreak hindered the growth of the enzyme market. During the COVID-19 pandemic, most companies involved in the manufacture of enzymes are currently focusing on manufacturing sanitizers to counter COVID-19. This led to a significant decline in global enzyme consumption, globally. For instance, in April 2020, BASF, the largest manufacturer of enzymes, started manufacturing hand sanitizers in New York and New Jersey to help the battle against COVID-19. Therefore, the COVID-19 outbreak limits the growth of the enzyme market. The development of new approaches to treat cancer using enzymes is a key trend gaining popularity in the enzymes market. Major universities and companies are investing in research focusing on evolving new solutions in enzyme therapies for cancer treatment. For example, in August 2020, scientists from McGill University and Osaka University in Japan were able to unlock the behavior of an enzyme involved in the spread of cancer cells by using the CMCF beamline at the Canadian Light Source (CLS) at the University of Saskatchewan. In May 2020, AbbVie Inc., an America-based biopharmaceutical company acquired Allergan plc for $63 billion. This acquisition significantly expands and diversifies AbbVie's revenue base and complements existing leadership positions in Immunology, with Humira and recently launched Skyrizi and Rinvoq, and Hematologic Oncology, with Imbruvica and Venclexta. Allergan plc is an Ireland-based pharmaceutical company engaged in the research, development, and manufacture of pharmaceutical and enzyme-based therapeutic products. Major players in the enzymes market are Sanofi, AbbVie Inc., Alexion Pharmaceuticals Inc, Horizon Pharma, Allergan plc, Pfizer Inc., Vivus, Digestive Care, Leadiant Biosciences, Roche Holdings AG and Codexis Inc. The regions covered in the enzymes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the enzymes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The global enzymes market is segmented - 1) By Product Type: Asparginase, Lipase, Protease, Nattokinase, Chitinase, Serratiopeptidase, Collagenase, Ligase, Others 2) By Application: Leukemia, Stomach Disorders, Antitumor, Skin Ulcers, Gaucher Disease, Fabry Disease, Others 3) By End User: Drug Manufacturers, Hospitals, Private Clinics, Research Laboratories

The protein inhibitors market consists of sales of protein inhibitors by entities (organizations, sole traders, and partnerships) that are engaged in the manufacturing of protein inhibitors. Protein synthesis inhibitors stop the development of cells by disrupting the process leading to the generation of new proteins. Protein inhibitors is a pharmaceutical drug that acts on the proteins (special target) in the body and finds applications in the treatment of various diseases such as cancer, autoimmune diseases, infectious diseases, and others. The main product types of protein inhibitors are protein kinase inhibitors, monoclonal antibodies, and others. Monoclonal antibodies are laboratory-created molecules designed to act as substitute antibodies, restoring, enhancing, modifying, or mimicking the immune system's attack on unwanted cells, such as cancer cells. The protein inhibitors are used in the treatment of oncology, inflammatory diseases, and others, that are distributed by hospital pharmacies, independent pharmacies, and online pharmacies. The protein inhibitors market research report is one of a series of new reports from The Business Research Company that provides protein inhibitors market statistics, including protein inhibitors industry global market size, regional shares, competitors with a protein inhibitors market share, detailed protein inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the protein inhibitors industry. This protein inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global protein inhibitors market is expected to grow from $62.54 billion in 2021 to $68.17 billion in 2022 at a compound annual growth rate (CAGR) of 9.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, affecting many markets across the globe. The protein inhibitors market is expected to reach $96.73 billion in 2026 at a CAGR of 9.1%. The increasing prevalence of chronic diseases is predicted to contribute to the growth of the protein inhibitors market over the forecast period. Chronic diseases such as cancer, cardiovascular diseases, and autoimmune diseases are becoming more prevalent. According to the World Health Organization, chronic diseases are expected to become the seventh leading cause of death globally by the end of 2030. Moreover, according to the National Health Council’s report published in 2019, there were approximately 133 million Americans affected by chronic diseases, estimated to be 40% of the total population of the country. In the USA, the number reached 157 million in 2020, with 87 million people having multiple conditions. Protein inhibitors are used for the treatment of these diseases attributing to fewer adverse effects and higher efficacy. Therefore, an increasing number of people with chronic diseases are anticipated to propel the demand for protein inhibitors market. The high cost of protein inhibitors used for cancer is anticipated to limit the growth of the protein inhibitors market shortly. Monoclonal antibodies are a type of protein made in the laboratory to bind substances in the body including cancer cells and are used to treat various types of cancer. Monoclonal antibody therapies are considered to be costlier when used for cancer. For instance, according to the National Center for Biotechnology Information, the average price of monoclonal antibodies was $96,731 for 34 monoclonal antibody indication combinations. Oncology and hematology monoclonal antibodies represented 40% of approved monoclonal antibody indication combinations, yet accounted for more than 85% of those priced at $100,000 or higher. The price of oncology or hematology monoclonal antibodies was $149,622 higher than those used in metabolic or cardiovascular disorders, $106,830 higher than in ophthalmology, $128,856 higher than in infectious diseases or allergies, and $98,981 higher than in immunology. Thus, the high cost of protein inhibitors including monoclonal antibodies for the treatment of cancer is expected to hinder the market’s growth. Companies in the protein inhibitors market are increasingly investing in various strategic initiatives such as partnerships and collaborations to develop new drugs to meet the market demand. Strategic collaborations and partnership agreements help companies to expand their existing product portfolio and geographical presence. For instance, in February 2020, Catalent, Inc., a USA-based provider of delivery technologies, drug manufacturing, gene therapies, biologics, and consumer healthcare products announced a partnership agreement with Zumutor Biologics Inc., an immune-oncology company based in the USA to manufacture ZM008, a monoclonal antibody targeting solid tumors. Moreover, in February 2021, Eli Lilly and Company, a USA-based pharmaceutical company, and Rigel Pharmaceuticals, Inc, a USA-based biotechnology company, announced a global exclusive license agreement and strategic collaboration to co-develop and commercialize Rigel's R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for all indications, including autoimmune and inflammatory diseases. In December 2019, Sanofi S.A. a France-based pharmaceutical company announced the acquisition of Synthorx, Inc., a biotechnology company for $2.5 billion. The acquisition is aimed at boosting the immune-oncology pipeline of Sanofi S.A. Synthorx, Inc.’s novel discovery platform has developed a molecule with the potential to become a foundation for the next generation of combination therapies for the treatment of cancer. THOR-707 by expanding the number of T-cells and natural killer cells in the body can be combined with other oncology medicines for treating cancer. Synthorx, Inc. is a USA-based company specializing in protein therapeutics for improving and prolonging the lives of people with autoimmune diseases, inflammatory diseases, and cancer. Major players in the protein inhibitors market are Bayer AG, Astra Zeneca, Roche, Teva, Apotex, Novartis, Glaxosmithkline, Pfizer, Boehringer Ingelheim and F. Hoffmann-La Roche. The regions covered in the protein inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the protein inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The global protein inhibitors market is segmented - 1)By Product: Protein Kinase Inhibitors, Monoclonal Antibody, Others 2)By Application: Oncology, Inflamatory Diseases, Others 3)By Distribution Channel: Hospital Pharmacies, Independent Pharmacies, Online Pharmacies

The microbiome market consists of sales of microbiomes drugs and related services. Microbiome therapy aims at restoring balanced gut microbiota and is expected to decrease the risk of infection recurrence and greatly increase the quality of life of patients. The main types of microbiomes are fecal microbiota transplantation (FMT) and microbiome drugs. The technique of transferring faecal bacteria and other germs from one healthy person to another is known as faecal microbiota transplantation or stool transplantation. The different technologies include genomics, proteomics, and metabolomics and are used in inflammatory bowel disease, diabetes, multiple sclerosis, rheumatoid arthritis, and others. The microbiome market research report is one of a series of new reports from The Business Research Company that provides microbiome market statistics, including microbiome industry global market size, regional shares, competitors with a microbiome market share, detailed microbiome market segments, market trends, and opportunities, and any further data you may need to thrive in the microbiome industry. This microbiome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global microbiome market is expected to grow from $5.54 billion in 2021 to $6.18 billion in 2022 at a compound annual growth rate (CAGR) of 11.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, affecting many markets across the globe. The microbiome market is expected to reach $10.09 billion in 2026 at a CAGR of 13.1%. The increasing prevalence of inflammatory bowel disease (IBD) is a key factor driving the growth of the microbiome market. Inflammatory bowel disease (IBD) is a multifactorial and autoimmune infection group consisting of two major entities such as ulcerative colitis (UC) and Crohn's disease (CD). Fecal microbiota transplantation (FMT) and probiotics were discovered as potential applications in many immune-mediated disorders, such as IBD, to restore microbial balance. These microbial therapies have shown the potential to reduce both the dysbiotic condition and the development of inflammatory mediators, thereby enabling remission, particularly in UC. In 2019, approximately 1.6 million people in the United States suffered from untreatable inflammatory bowel disease (IBD), including Crohn's or ulcerative colitis. Therefore, the increasing prevalence of inflammatory bowel disease (IBD) is expected to drive the growth of the microbiome market. The high cost of microbial therapy is a key factor hampering the growth of the microbiome market. The price of fecal transplantation, a microbial therapy, may vary considerably depending on the delivery method used by users and where users receive it. Fecal microbiota transplant processes can charge around $600-$1,000 based on the method of treatment, area, insurance coverage, and other variables. Therefore, the high cost of microbial therapy is expected to hinder the growth of the microbiome market. The growing technological improvement is a major trend gaining popularity in the microbiome market. Major companies in the microbiome sector are focusing on developing advanced technology solutions for microbiomes. For instance, Seed, a new microbiome company, has introduced Probiotic and Prebiotic Daily Synbiotic for both females and males. The Daily Synbiotic Seed is the first to follow a microbe-system strategy with strain-specific advantages beyond digestive health such as cardiac safety, dermatological health, immune control, reproductive health, the integrity of the gut barrier, and oxidative stress. In January 2021, Novozymes, a Denmark-based biotechnology company acquired Microbiome Labs for an undisclosed amount. Microbiome Labs’ acquisition is a crucial step in expanding Novozymes’ Human Health platform, giving it exposure to a wide range of patented solutions as well as access to the firm’s network of health professionals. Microbiome Labs is a US-based probiotics company. Major players in the microbiome market are MicroBiome Therapeutics LLC, Seres Therapeutics, Enterome Bioscience, Second Genome, Vedanta Biosciences Inc, AbbVie Inc., Rebiotix, Inc., Ritter Pharmaceuticals, LNC Therapeutics Inc. and ViThera Pharmaceuticals Inc. The regions covered in the microbiome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the microbiome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global microbiome market is segmented - 1) By Type: Fecal Microbiota Transplantation (FMT), Microbiome drugs 2) By Application: Inflammatory Bowel Disease, Diabetes, Multiple Sclerosis, Rheumatoid Arthritis, Others 3) By Technology: Genomics, Proteomics, Metabolomics

The cellular immunotherapy market consists of revenues generated by the companies engaged in developing, manufacturing, and sales of cellular immunotherapy drugs. Cellular immunotherapy is also known as adoptive cell therapy, a form of treatment that utilizes the cells of the immune system to eliminate diseases including non-Hodgkin lymphoma, cancer, and acute lymphoblastic leukemia. The main therapies of cellular immunotherapy are tumor-infiltrating lymphocyte (TIL) therapy, engineered T cell receptor (TCR) therapy, chimeric antigen receptor (CAR) T cell therapy, and natural killer (NK) cell therapy. Tumor-infiltrating lymphocyte (TIL) therapy is a type of adoptive cellular therapy that involves extracting infiltrated lymphocytes from tumors, culturing and amplifying them in vitro, and then infusing them back into patients to treat them. The various primary indication includes b-cell malignancies, prostate cancer, renal cell carcinoma, liver cancer, non-Hodgkin lymphoma, and others and is used for the treatment of prostate cancer, breast cancer, skin cancer, ovarian cancer, brain tumour, lung cancer, and others. The cellular immunotherapy market research report is one of a series of new reports from The Business Research Company that provides cellular immunotherapy market statistics, including cellular immunotherapy industry global market size, regional shares, competitors with a cellular immunotherapy market share, detailed cellular immunotherapy market segments, market trends and opportunities, and any further data you may need to thrive in the cellular immunotherapy industry. This cellular immunotherapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global cellular immunotherapy market is expected to grow from $3.68 billion in 2021 to $4.30 billion in 2022 at a compound annual growth rate (CAGR) of 17%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, affecting many markets across the globe. The cellular immunotherapy market is expected to reach $7.60 billion in 2026 at a CAGR of 15.3%. Increasing research and successful clinical trials in cellular immunotherapy are expected to drive the growth of the cellular immunotherapy market over the forecast period. Companies are focusing on developing new cellular immunotherapies for treating different diseases. The rapid growth in the development of cellular immunotherapy in clinical and preclinical stages in 2020 as compared to that in 2019 is projected to expand the landscape of cellular immunotherapy. Subsequently, generating higher revenues for the cellular immunotherapy market. The high cost of cellular immunotherapies is anticipated to hinder cellular immunotherapy’s market growth. CAR-T therapy is a type of cellular immunotherapy and only two have been approved in the USA. The price of Yescarta and Kymriah is more than $350,000 per treatment in the USA, which is highly unaffordable for a majority of the patients, especially with low income. The high cost of cellular immunotherapies discourages patients to opt for this drug, thereby, impacting the demand and the market negatively. Companies in the cellular immunotherapy market are focusing on developing off-the-shelf allogeneic therapies for new and improved cancer treatment. Off-the-shelf allogeneic therapies are produced from the cells of donors instead of the patient cells as in the case of autologous therapy. Their non-customized nature provides advantages such as cost-effectiveness, large scale, fast, and quality control production. For instance, in November 2019, Precision Biosciences, Inc., a biotechnology company, created a new generation of allogeneic CAR-T therapy and is conducting an ongoing trial of this therapy by creating its first off-the-shelf allogeneic CAR-T therapy candidate known as PBCAR0191. This is in collaboration with Servier, an international pharmaceutical company, and is mainly for patients in need of advanced cancer treatment options. Additionally, in August 2020, Acepodia, a US-based next-generation cell immuno-technology company, initiated a phase 1 clinical trial for evaluating ACE1702 an allogeneic, off-the-shelf NK cell therapy for the treatment of solid tumors. In April 2020, resTORbio, Inc., a US-based biopharmaceutical company specializing in the development and commercialization of drugs used for the treatment of aging-related diseases, merged with Adicet Bio, Inc., a biopharmaceutical company, for an undisclosed amount. Both the companies continue their operations as ‘Adicet Bio’. This merger is expected to help the companies in advancing allogeneic gamma-delta CAR-T cell therapy technology. Adicet Bio, Inc. is a US-based company specializing in the development of Adicet’s off-the-shelf allogeneic gamma delta T cell therapies for oncology and other indications. Major players in the cellular immunotherapy market are Novartis AG, Gilead Sciences Inc. (Kite Pharma), Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co. Ltd, Green Cross Corp (GC Pharma), AstraZeneca, Bristol-Myers Squibb, Pfizer Inc. and Roche. The regions covered in the cellular immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cellular immunotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA The global cellular immunotherapy market is segmented - 1) By Therapy: Tumour-Infiltrating Lymphocyte (TIL) Therapy, Engineered T Cell Receptor (TCR) Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapy, Natural Killer (NK) Cell Therapy 2) By Primary Indication: B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, Non-Hodgkin lymphoma, Others 3) By Application: Prostate Cancer, Breast Cancer, Skin Cancer, Ovarian Cancer, Brain Tumour, Lung Cancer, Others

The digestive enzymes market consists of the sale of digestive enzymes and related services used to ease up the digestion of food in the stomach. Digestive enzymes are enzymes in the digestive system that break large molecules into smaller digestible molecules to be absorbed by the body. The digestive enzymes market commercially provides these enzymes as dietary supplements or drugs to be taken orally when the body fails to produce enough enzymes naturally for the digestion of fats, proteins, and carbohydrates. The main types of digestive enzymes are carbohydrates, protease, lipase, and other enzyme types. Lipase is a protein produced by the pancreas; a small organ located near the stomach that aids in fat digestion. The enzymes originated from animals, fungi, microbial, and plants that are used for indigestion, chronic pancreatitis, irritable bowel syndrome, and other applications. The various distribution channel includes retail stores and online stores. The digestive enzymes market research report is one of a series of new reports from The Business Research Company that provides digestive enzymes market statistics, including digestive enzymes industry global market size, regional shares, competitors with a digestive enzymes market share, detailed digestive enzymes market segments, market trends and opportunities, and any further data you may need to thrive in the digestive enzymes industry. This digestive enzymes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global digestive enzymes market is expected to grow from $0.75 billion in 2021 to $0.82 billion in 2022 at a compound annual growth rate (CAGR) of 9.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, affecting many markets across the globe. The digestive enzymes market is expected to reach $1.17 billion in 2026 at a CAGR of 9.3%. The rising prevalence of the gastrointestinal disorder among different age groups drives the growth of the digestive enzymes market. Gastrointestinal disorders include disorders in the gastrointestinal tract starting from the mouth, oesophagus, stomach, small intestine, large intestine, and anus caused due to lack of digestive enzymes. Gastrointestinal disorders require the digestive enzymes to be taken orally as a dietary supplement or as a drug. The increased rates of gastrointestinal disorders are linked to smoking, diet and genetics, sanitation, increased use of antibiotics, and the changing environmental factors due to industrialization and urbanization. According to the American Gastroenterological Association’s survey published in April 2020 on the worldwide prevalence and burden of functional gastrointestinal disorders, among 73,076 adult respondents, about 40.3% of people met the diagnostic criteria for at least 1 functional gastrointestinal disorder (FGIDs). FGID was more prevalent among women than men. A large-scale multinational study found that more than 40% of the population is having FGIDs across the globe. Therefore, the increase in the prevalence of digestive diseases contributes to the growth of the market. The potential side effects of digestive enzyme supplements and drugs restrain the growth of the digestive enzymes market. Continuous intake of digestive enzymes increases dependency on the digestive enzymes resulting in a weaker digestive system over time. The weakened digestive system leads to digestive distress, gas, nausea, bloating, decreased stomach acid, and allergic reactions accompanied by diarrhea and vomiting. For instance, the digestive enzyme bromelain causes thinning of the blood and increases the risk of excess bleeding. The thinning of the blood is the result of the anti-platelet activity caused by the drug. Thus, the side effects caused by the excess and continuous intake of digestive enzymes negatively impact the growth of the digestive enzyme market. The companies in the digestive enzymes market are investing in developing customized digestive enzymes. These customized digestive enzymes are condition-specific enzymes to support digestion for digestive sensitive patients and may contain multiple enzymes in the same product. The companies involved in manufacturing digestive enzymes are developing customized digestive enzymes to ease the digestion of different types of food. For instance, Sabinsa, a USA-based provider of herbal extracts, cosmeceuticals, minerals, and dietary supplements, formulated DigeZyme. DigeZyme is a multi-enzyme complex comprising five different enzymes, namely, cellulase, lactase, amylase, lipase, and protease. It is widely used by people who have difficulty in digesting carbohydrates, fats, and proteins, respectively. The companies are increasingly investing in developing customized digestive enzymes. In January 2020, Nestlé, a Switzerland-based food and drink processing corporation, entered into an asset purchase agreement with Allergan, an Ireland-based pharmaceutical company that acquires, develops, and markets brand name drugs, to acquire Zenpep for an amount undisclosed. Through the acquisition, Nestle aims to expand its medical nutrition portfolio by including Zenpep products to support food ingestion, digestion, and absorption. Zenpep is a medication for people who cannot digest food properly due to the lack of digestive enzymes. Major players in the digestive enzymes market are Garden of Life, Biotics Research Corporation, Klaire Laboratories, Abbott Nutrition, AbbVie Inc., Allergan PLC, Johnson & Johnson Inc. Amway Corporation, Food State Inc., Matsun Nutrition, Metagenics Inc., Twinlab Corporation, Food State Inc., AST Enzymes, VEMO 99 OOD, Advanced Vital Enzymes Pvt. Ltd., Zeus Biotech Limited, Vox Nutrition Inc., Enzyme Bioscience Pvt. Ltd., Metagenics, XYMOGEN Inc., Douglas Laboratories, Thorne Research, Integrative Therapeutics LLC, Pure Encapsulations, Ortho Molecular Products Inc., Designs for Health Inc., Master Supplements Inc., and Proteozymes. North America was the largest region in the digestive enzymes market in 2021. Middle East is expected to be the fargest growing region in the forecast period. The regions covered in the digestive enzymes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the digestive enzymes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global digestive enzymes market is segmented - 1) By Enzyme Type: Carbohydrates, Protease, Lipase, Other Enzyme Types 2) By Origin: Animal, Fungi, Microbial, Plant 3) By Application: Indigestion, Chronic Pancreatitis, Irritable Bowel Syndrome, Other Applications 4) By Distribution Channel: Retail Stores, Online Stores